Development Level

Tbio 8 | 11,445
Tchem 2 | 1,598
Tclin 1 | 613

IMPC Phenotype

decreased blood urea nitrogen ... 1 | 51
decreased erythrocyte cell num... 1 | 62
embryonic lethality prior to o... 1 | 239
embryonic lethality prior to t... 1 | 278
increased mean corpuscular vol... 1 | 92
increased monocyte cell number 1 | 63
preweaning lethality, complete... 1 | 979

Disease

ovarian cancer 8 | 8,520
Carcinoma 7 | 11,493
oligodendroglioma 6 | 2,850
osteosarcoma 6 | 7,950
psoriasis 6 | 6,694
Cancer 5 | 2,499
glioblastoma 5 | 5,792
Fibrodysplasia ossificans progressiva 4 | 17
acute quadriplegic myopathy 4 | 1,158
ependymoma 4 | 4,679
group 4 medulloblastoma 4 | 1,855
medulloblastoma, large-cell 4 | 6,241
Breast cancer 3 | 3,578
Cryptorchidism 3 | 296
Liver Cirrhosis, Experimental 3 | 769
Pick disease 3 | 1,894
astrocytic glioma 3 | 2,597
atypical teratoid / rhabdoid tumor 3 | 5,112
cystic fibrosis 3 | 1,696
group 3 medulloblastoma 3 | 4,104
pediatric high grade glioma 3 | 1,064
Abnormality of male internal genitalia 2 | 4
Amyotrophic lateral sclerosis 2 | 451
Ankylosis 2 | 28
Astrocytoma, Pilocytic 2 | 3,081
Autosomal recessive predisposition 2 | 1,442
Breast Neoplasms 2 | 445
Congenital deafness 2 | 185
Deafness 2 | 198
Decreased joint mobility 2 | 53
Duchenne muscular dystrophy 2 | 601
Endometriosis 2 | 540
Familial primary pulmonary hypertension 2 | 11
Female Urogenital Diseases 2 | 18
Hearing Loss, Partial 2 | 185
Hereditary hemorrhagic telangiectasia 2 | 13
Hernia, Inguinal 2 | 89
Hyperandrogenism 2 | 34
Hypertensive disease 2 | 292
Hypospadias 2 | 53
Idiopathic pulmonary arterial hypertension 2 | 40
Increase in blood pressure 2 | 119
Infertility 2 | 188
Inguinal hernia 2 | 14
Kidney cancer 2 | 2,613
Male Pseudohermaphroditism 2 | 19
Male infertility 2 | 206
Mammary Neoplasms 2 | 425
Ovarian hyperstimulation syndrome 2 | 19
Persistent Mullerian duct syndrome 2 | 3
Polycystic ovary syndrome 2 | 360
Premature ovarian failure 2 | 65
Primary pulmonary hypertension 2 | 14
Pseudohermaphroditism 2 | 16
Pulmonary hypertension 2 | 85
Schizophrenia 2 | 1,160
Stomach Neoplasms 2 | 300
Telangiectasis 2 | 36
Vascular resistance pulmonary increased 2 | 3
active Crohn's disease 2 | 922
acute myeloid leukemia 2 | 783
adult high grade glioma 2 | 3,801
astrocytoma 2 | 1,146
autosomal dominant Emery-Dreifuss muscular dystrophy 2 | 510
hearing impairment 2 | 199
interstitial cystitis 2 | 2,312
intraductal papillary-mucinous neoplasm (IPMN) 2 | 3,291
juvenile dermatomyositis 2 | 1,187
lung adenocarcinoma 2 | 2,716
lung cancer 2 | 4,740
malignant mesothelioma 2 | 3,232
non-small cell lung cancer 2 | 2,890
pancreatic cancer 2 | 2,398
primitive neuroectodermal tumor 2 | 3,035
pulmonary arterial hypertension 2 | 75
subependymal giant cell astrocytoma 2 | 2,287
tuberculosis 2 | 2,010
Abnormal vertebral bodies 1 | 16
Androgen insensitivity syndrome 1 | 12
Aortic valve stenosis 1 | 28
Bannayan-Riley-Ruvalcaba syndrome 1 | 8
Broad femoral neck 1 | 4
Cone-shaped epiphyses 1 | 24
Craniometaphyseal dysplasia 1 | 5
Degenerative disc disease 1 | 35
Diffusely thickened skin 1 | 20
Hamartomatous polyp 1 | 10
Hypoplastic finger 1 | 17
Left ventricular noncompaction 1 | 26
Legionnaires' disease 1 | 20
Multiple vertebral anomalies 1 | 16
Multiple, subcutaneous nodules 1 | 53
Pachyderma 1 | 20
Pericardial effusion 1 | 14
Prostatitis 1 | 18
Short finger 1 | 17
Short tubular bones 1 | 22
Subcutaneous nodule 1 | 53
Transplanted organ rejection 1 | 10
Ureteral obstruction 1 | 33

Tissue

Endocrine System 11 | 18,159
Blood and immune system 10 | 16,909
Digestive Tract 10 | 17,369
Nervous System 10 | 16,725
Skin and soft tissues 10 | 17,230
Cardiovascular System 9 | 15,192
Female tissues 9 | 17,400
Liver and Pancreas 9 | 16,750
Male tissues 9 | 17,142
Respiratory system 9 | 16,393
Urinary Tract 9 | 16,678

Target Family

Transcription Factor 5 | 1,400
Kinase 3 | 634
Non-IDG 2 | 12,091
Enzyme 1 | 4,145

PathwayCommons: pid Pathway

http://pathwaycommons.org/pc2/... 11 | 11
http://pathwaycommons.org/pc2/... 137 | 137
http://pathwaycommons.org/pc2/... 125 | 125
http://pathwaycommons.org/pc2/... 102 | 102
http://pathwaycommons.org/pc2/... 87 | 87
http://pathwaycommons.org/pc2/... 87 | 87
http://pathwaycommons.org/pc2/... 85 | 85
http://pathwaycommons.org/pc2/... 82 | 82
http://pathwaycommons.org/pc2/... 80 | 80
http://pathwaycommons.org/pc2/... 80 | 80
http://pathwaycommons.org/pc2/... 80 | 80
http://pathwaycommons.org/pc2/... 80 | 80
http://pathwaycommons.org/pc2/... 77 | 77
http://pathwaycommons.org/pc2/... 74 | 74
http://pathwaycommons.org/pc2/... 74 | 74
http://pathwaycommons.org/pc2/... 71 | 71
http://pathwaycommons.org/pc2/... 71 | 71
http://pathwaycommons.org/pc2/... 70 | 70
http://pathwaycommons.org/pc2/... 70 | 70
http://pathwaycommons.org/pc2/... 69 | 69
http://pathwaycommons.org/pc2/... 67 | 67
http://pathwaycommons.org/pc2/... 67 | 67
http://pathwaycommons.org/pc2/... 67 | 67
http://pathwaycommons.org/pc2/... 66 | 66
http://pathwaycommons.org/pc2/... 66 | 66
http://pathwaycommons.org/pc2/... 66 | 66
http://pathwaycommons.org/pc2/... 66 | 66
http://pathwaycommons.org/pc2/... 65 | 65
http://pathwaycommons.org/pc2/... 65 | 65
http://pathwaycommons.org/pc2/... 65 | 65
http://pathwaycommons.org/pc2/... 64 | 64
http://pathwaycommons.org/pc2/... 64 | 64
http://pathwaycommons.org/pc2/... 63 | 63
http://pathwaycommons.org/pc2/... 63 | 63
http://pathwaycommons.org/pc2/... 63 | 63
http://pathwaycommons.org/pc2/... 62 | 62
http://pathwaycommons.org/pc2/... 61 | 61
http://pathwaycommons.org/pc2/... 60 | 60
http://pathwaycommons.org/pc2/... 59 | 59
http://pathwaycommons.org/pc2/... 59 | 59
http://pathwaycommons.org/pc2/... 58 | 58
http://pathwaycommons.org/pc2/... 57 | 57
http://pathwaycommons.org/pc2/... 56 | 56
http://pathwaycommons.org/pc2/... 56 | 56
http://pathwaycommons.org/pc2/... 55 | 55
http://pathwaycommons.org/pc2/... 54 | 54
http://pathwaycommons.org/pc2/... 54 | 54
http://pathwaycommons.org/pc2/... 54 | 54
http://pathwaycommons.org/pc2/... 54 | 54
http://pathwaycommons.org/pc2/... 53 | 53
http://pathwaycommons.org/pc2/... 53 | 53
http://pathwaycommons.org/pc2/... 53 | 53
http://pathwaycommons.org/pc2/... 51 | 51
http://pathwaycommons.org/pc2/... 50 | 50
http://pathwaycommons.org/pc2/... 50 | 50
http://pathwaycommons.org/pc2/... 50 | 50
http://pathwaycommons.org/pc2/... 49 | 49
http://pathwaycommons.org/pc2/... 49 | 49
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 47 | 47
http://pathwaycommons.org/pc2/... 47 | 47
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 45 | 45
http://pathwaycommons.org/pc2/... 45 | 45
http://pathwaycommons.org/pc2/... 44 | 44
http://pathwaycommons.org/pc2/... 43 | 43
http://pathwaycommons.org/pc2/... 43 | 43
http://pathwaycommons.org/pc2/... 43 | 43
http://pathwaycommons.org/pc2/... 43 | 43
http://pathwaycommons.org/pc2/... 42 | 42
http://pathwaycommons.org/pc2/... 42 | 42
http://pathwaycommons.org/pc2/... 42 | 42
http://pathwaycommons.org/pc2/... 42 | 42
http://pathwaycommons.org/pc2/... 41 | 41
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 39 | 39
http://pathwaycommons.org/pc2/... 39 | 39
http://pathwaycommons.org/pc2/... 39 | 39
http://pathwaycommons.org/pc2/... 38 | 38
http://pathwaycommons.org/pc2/... 38 | 38
http://pathwaycommons.org/pc2/... 38 | 38
http://pathwaycommons.org/pc2/... 38 | 38
http://pathwaycommons.org/pc2/... 37 | 37
http://pathwaycommons.org/pc2/... 37 | 37
http://pathwaycommons.org/pc2/... 37 | 37
http://pathwaycommons.org/pc2/... 36 | 36

This is where graphics are reside..
Name Gene Development Level Target Family Log Novelty  Pubmed Score  Antibody Count  Knowledge Availability 
Bone morphogenetic protein receptor type-2 BMPR2 Tchem Kinase -2.66587 458.1 390
T-cell leukemia homeobox protein 2 TLX2 Tbio Transcription Factor -2.18879 155.8 57
Muellerian-inhibiting factor AMH Tbio Non-IDG -3.43406 2729.3 264
Anti-Muellerian hormone type-2 receptor AMHR2 Tbio Kinase -2.11206 117.9 240
Mothers against decapentaplegic homolog 4 SMAD4 Tbio Transcription Factor -3.16129 1349.8 605
Mothers against decapentaplegic homolog 5 SMAD5 Tbio Transcription Factor -2.16078 121.7 359
Peptidyl-prolyl cis-trans isomerase FKBP1A FKBP1A Tclin Enzyme -2.77923 382.8 271
Mothers against decapentaplegic homolog 9 SMAD9 Tbio Transcription Factor -2.36614 232.5 242
Activin receptor type-1 ACVR1 Tchem Kinase -2.47071 290.9 428
Bone morphogenetic protein 7 BMP7 Tbio Non-IDG -3.16189 1536.8 736